Atrial FlutterCF-CTIANCT02917538
A Randomized Trial of Contact Force in Atrial Flutter Ablation
A study testing RFA in people with Atrial Flutter, run by Aarhus University Hospital Skejby at 1 site in Denmark.
Trial summary
A clinical randomized trial to evaluate if CF guided Radio Frequency Ablation (RFA) to a specific of LSI in atrial flutter i superior to standard RFA. Read more about this study
- Who is it for?
- Ages 40 years and older
- Conditions the study is for
- Atrial Flutter
- What is being tested?
- RFA
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 156 participants
- Where
- 1 siteDenmark
- Study dates
- 1 Sep 2016to 1 Jun 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with typical Atrial flutter undergoing first time Cavo Tricuspid Isthmus Ablation
Who cannot join
- Congenital heart disease
- Atrial fibrillation is the dominant arrhythmia
- Prior right atrial atriotomy
- Significant mitral valve disease
- NYHA IV
- Secondary AFL (e.g. post-surgery, infections, hyperthyroidism)
- Age < 40 years
Trial locations and contacts
1 site in 1 country.
About this study
A clinical randomized trial to evaluate if CF guided Radio Frequency Ablation (RFA) to a specific of LSI in atrial flutter i superior to standard RFA.
Read the detailed description
Atrial flutter (AFL) is a macro-reentry tachycardia in the right atrium [1,2]. AFL is seen in 0,4 -1,2% of ECG´s in the hospital[3]. Prevalence is higher in patients with structural heart disease, as hypertension, coronary heart disease and cardiomyopathy and also in patients with chronic obstructive lung disease. AFL occurs frequently among patients operated for congenital heart disease.
Cavotricuspid isthmus ablation (CTIA) using radiofrequency (RF) energy is a well-established first line therapy of typical AFL.
The most common arrhythmia requiring treatment is atrial fibrillation (AF). When performing catheter ablation for AF, contact force (CF) applied during radiofrequency energy delivery is a powerful predictor of the electrical isolation of the pulmonary veins and of the clinical response. However, prospective data documenting the superiority of ablation guided by the real time CF monitoring over the standard procedure both for AF and for AFL, are missing. In this regard, showing superiority of ablation guided by the real time CF monitoring over the standard procedure in the simple lesion model of CTIA can serve as a proof of concept for more complex lesion sets, as in AF ablation. The Lesion Size Index (LSI) estimates the size of the lesion created by ablation. It takes account for the nonlinear relationship between the size of the lesion and its three main determinants (CF, power and duration [4,5]), and may therefore be an effective mean to precisely dose the amount of the delivered radiofrequency energy. This may prevent both insufficient lesion creation and complications due to excessive energy delivery. The aim of the present study is to evaluate if CF guided ablation targeting a specific value of LSI is superior to standard radiofrequency catheter ablation (RFCA).
Hypothesis:
CF guided ablation targeting a specific value of LSI is superior to standard RFCA with respect to creating lasting ablation lesions in the cavo-tricuspid isthmus region.
Purpose:
The present study is designed to determine if CF guided ablation targeting a specific value of LSI is superior to standard RFCA with respect to creating lasting ablation lesions in the cavo-tricuspid isthmus region.
Inclusion criteria:
Patients with typical AFL undergoing first CTIA are included.
Exclusion criteria:
Congenital heart disease AF is the dominant arrhythmia Prior right atrial atriotomy Significant mitral valve disease New York Heart Association (NYHA) class IV Secondary AFL (e.g. post-surgery, infections, hyperthyroidism) Age < 40 years Patient does not want to participate.
Study size:
156 patients.
Study design:
Randomized controlled double-blinded study
Inclusion and randomization:
Consecutive patients referred to Department of Cardiology, Aarhus University Hospital, Skejby for ablation of AFL will be screened. All pts without documented AF will undergo a 5 day ambulatory ECG before the scheduled ablation procedure.
Pts with AF documented either on a 12-lead ECG or during ambulatory ECG will be informed about pulmonary vein isolation, if suitable and in the case of accept will be referred for such.
Pts without documented AF fulfilling the inclusion criteria and pts who are not candidates for or not wanting Pulmonary Vein Isolation (PVI) will be invited to an interview with the daily contact person. They will here be informed about the study both orally and written. The interview will take place in a room specially selected for this interview to ensure there will be no interruptions. At the end of the interview pts will be asked to sign a written consent form. Subsequently patients are randomized (computer-based) to two Groups:
- In group 1, the ablation will be guided by real time CF monitoring and LSI, with a target LSI of 7,0 with a target range 6,8-7.2 . The aim will be a stable contact, and CF 10-30 g. Intermittent contact will be avoided.
- In group 2, the operator is blinded to the real-time CF.
Randomization Study data are recorded in a web-based case record form (CRF) with loggin of all data entries. The CRF is also used for randomization using computerized permuted blocks of different sizes. Randomization is stratified according to gender. An external data manager is responsible for the CRF and has programmed the random-number generator used.
Follow-up
4 weeks after ablation, a 5 day ambulatory ECG will be performed. 3 months after ablation an Electro Physiological study (EP) will be performed along with administration of adenosine to check the completeness of Bidirectional Isthmus Block (BDIB). In case of reconduction BDIB will be completed. Recurrent isthmus conduction will be classified as located in the anterior half of the isthmus, the posterior half of the isthmus or both.
The follow-up will be 12 months. Patients will be seen at the outpatient clinic 12 month after the ablation, where a 12-lead ECG will be performed. Before this 12 months' visit, a 5 day ambulatory ECG will be performed.
- Conditions
- Atrial Flutter
- Being tested
- RFA
- Medical subject headings
- Atrial Flutter
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RFAProcedure or surgery
Both groups will receive radiofrequency ablation treatment
| Study group | Role | What they receive |
|---|---|---|
| Intervention group | Experimental | In the intervention group: The operator will perform the RFA treatment guided by real-time CF parameters. Receives: Procedure: RFA |
| Control group | Active comparator | In the control group: The Operator will perform the RFA treatment blinded to the real-time CF parameters. Receives: Procedure: RFA |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of recurrent isthmus conduction
Rate of recurrent isthmus conduction measured at invasive electrophysiological study 3 months after ablation
Measured: 3 months
Secondary outcomes (13)
Rate of recurrent isthmus conduction in the anterior, middle or posterior third of the isthmus.
Measured at invasive electrophysiological study 3 months after ablation
Measured: 3 months
Freedom from recurrence of Atrial flutter
Documented by either 12 lead ECG or ambulatory ECG
Measured: 3 and 12 months
Occurrence of bidirectional isthmus block with the first ablation line.
Measured at the primary procedure
Measured: 1 hour
Rate of permanent reconduction on the table
Rate of permanent reconduction on the table spontaneous and with adenosine within a waiting period of 10 minutes.
Measured: 10 minutes
Rate of transient reconduction on the table with adenosine
Transient reconduction detected by administering adenosine
Measured: 10 minutes
Ablation time needed to achieve bidirectional isthmus block
Evaluated at the end of the primary procedure
Measured: 1 hour
Total ablation time
Evaluated at the end of the primary procedure
Measured: 1 hour
Total procedure time
Evaluated at the end of the primary procedure
Measured: 1 hour
Quality of Life assesing patients symptoms
Quality of Life assessed by Short-Form-36 (SF-36) questionnaire
Measured: 12 months
Contact Force (CF)
CF values measured in grams in the two groups
Measured: 1 hour
Force-time-integral (FTI)
FTI values measured in gram seconds in the two groups
Measured: 1 hour
Lesion-size-index (LSI)
LSI values measured in the two groups. LSI does not have a unit but is computed using the FTI value and the power (measured in watts) used during ablation.
Measured: 1 hour
Reasons for reconduction
Measuring % of poor ablations for patients with reconduction
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Sep 2016 (estimated)
- Study start1 Sep 2016
- Primary completion20 May 2019
- Study completion1 Jun 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atrial FlutterStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 156 participants (actual)
Sponsor and investigators
- Lead sponsor
- Aarhus University Hospital Skejby
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mikkel Giehm-Reese, MD, Aarhus University Hospital Skejby
- Investigators
- Jens Cosedis Nielsen, MD, DMsci, Study chair, Aarhus University Hospital Skejby
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02917538
- Sponsor's protocol ID
- CTIA-2016
- Acronym
- CF-CTIA
- Status last verified
- Nov 2019
- First submitted
- 21 Sep 2016
- Last updated
- 5 Oct 2020
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- No: We are not authorized to share individual participant data
Study at a glance
From the registry record, last updated by the sponsor on 5 Oct 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Trial of Contact Force in Atrial Flutter Ablation
- ClinicalTrials.gov ID
- NCT02917538
- Acronym / sponsor ID
- CF-CTIA / CTIA-2016
- Conditions
- Atrial Flutter
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 156 participants (actual)
- Lead sponsor
- Aarhus University Hospital SkejbyUniversity, hospital or other
- Study start
- 1 Sep 2016 (actual)
- Primary completion
- 20 May 2019 (actual)
- Study completion
- 1 Jun 2020 (actual)
- First posted
- 28 Sep 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A clinical randomized trial to evaluate if CF guided Radio Frequency Ablation (RFA) to a specific of LSI in atrial flutter i superior to standard RFA.
Detailed description
Atrial flutter (AFL) is a macro-reentry tachycardia in the right atrium [1,2]. AFL is seen in 0,4 -1,2% of ECG´s in the hospital[3]. Prevalence is higher in patients with structural heart disease, as hypertension, coronary heart disease and cardiomyopathy and also in patients with chronic obstructive lung disease. AFL occurs frequently among patients operated for congenital heart disease.
Cavotricuspid isthmus ablation (CTIA) using radiofrequency (RF) energy is a well-established first line therapy of typical AFL.
The most common arrhythmia requiring treatment is atrial fibrillation (AF). When performing catheter ablation for AF, contact force (CF) applied during radiofrequency energy delivery is a powerful predictor of the electrical isolation of the pulmonary veins and of the clinical response. However, prospective data documenting the superiority of ablation guided by the real time CF monitoring over the standard procedure both for AF and for AFL, are missing. In this regard, showing superiority of ablation guided by the real time CF monitoring over the standard procedure in the simple lesion model of CTIA can serve as a proof of concept for more complex lesion sets, as in AF ablation. The Lesion Size Index (LSI) estimates the size of the lesion created by ablation. It takes account for the nonlinear relationship between the size of the lesion and its three main determinants (CF, power and duration [4,5]), and may therefore be an effective mean to precisely dose the amount of the delivered radiofrequency energy. This may prevent both insufficient lesion creation and complications due to excessive energy delivery. The aim of the present study is to evaluate if CF guided ablation targeting a specific value of LSI is superior to standard radiofrequency catheter ablation (RFCA).
Hypothesis:
CF guided ablation targeting a specific value of LSI is superior to standard RFCA with respect to creating lasting ablation lesions in the cavo-tricuspid isthmus region.
Purpose:
The present study is designed to determine if CF guided ablation targeting a specific value of LSI is superior to standard RFCA with respect to creating lasting ablation lesions in the cavo-tricuspid isthmus region.
Inclusion criteria:
Patients with typical AFL undergoing first CTIA are included.
Exclusion criteria:
Congenital heart disease AF is the dominant arrhythmia Prior right atrial atriotomy Significant mitral valve disease New York Heart Association (NYHA) class IV Secondary AFL (e.g. post-surgery, infections, hyperthyroidism) Age < 40 years Patient does not want to participate.
Study size:
156 patients.
Study design:
Randomized controlled double-blinded study
Inclusion and randomization:
Consecutive patients referred to Department of Cardiology, Aarhus University Hospital, Skejby for ablation of AFL will be screened. All pts without documented AF will undergo a 5 day ambulatory ECG before the scheduled ablation procedure.
Pts with AF documented either on a 12-lead ECG or during ambulatory ECG will be informed about pulmonary vein isolation, if suitable and in the case of accept will be referred for such.
Pts without documented AF fulfilling the inclusion criteria and pts who are not candidates for or not wanting Pulmonary Vein Isolation (PVI) will be invited to an interview with the daily contact person. They will here be informed about the study both orally and written. The interview will take place in a room specially selected for this interview to ensure there will be no interruptions. At the end of the interview pts will be asked to sign a written consent form. Subsequently patients are randomized (computer-based) to two Groups:
- In group 1, the ablation will be guided by real time CF monitoring and LSI, with a target LSI of 7,0 with a target range 6,8-7.2 . The aim will be a stable contact, and CF 10-30 g. Intermittent contact will be avoided.
- In group 2, the operator is blinded to the real-time CF.
Randomization Study data are recorded in a web-based case record form (CRF) with loggin of all data entries. The CRF is also used for randomization using computerized permuted blocks of different sizes. Randomization is stratified according to gender. An external data manager is responsible for the CRF and has programmed the random-number generator used.
Follow-up
4 weeks after ablation, a 5 day ambulatory ECG will be performed. 3 months after ablation an Electro Physiological study (EP) will be performed along with administration of adenosine to check the completeness of Bidirectional Isthmus Block (BDIB). In case of reconduction BDIB will be completed. Recurrent isthmus conduction will be classified as located in the anterior half of the isthmus, the posterior half of the isthmus or both.
The follow-up will be 12 months. Patients will be seen at the outpatient clinic 12 month after the ablation, where a 12-lead ECG will be performed. Before this 12 months' visit, a 5 day ambulatory ECG will be performed.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, care provider)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention group | Experimental | Procedure: RFAIn the intervention group: The operator will perform the RFA treatment guided by real-time CF parameters. |
| Control group | Active comparator | Procedure: RFAIn the control group: The Operator will perform the RFA treatment blinded to the real-time CF parameters. |
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Patients with typical Atrial flutter undergoing first time Cavo Tricuspid Isthmus Ablation
Key exclusion criteria (7 listed)
- Congenital heart disease
- Atrial fibrillation is the dominant arrhythmia
- Prior right atrial atriotomy
- Significant mitral valve disease
- NYHA IV
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RFABoth groups will receive radiofrequency ablation treatment | Procedure or surgery | Control group, Intervention group |
Primary outcome
Rate of recurrent isthmus conduction
Time frame: 3 months
Rate of recurrent isthmus conduction measured at invasive electrophysiological study 3 months after ablation
13 secondary outcomes
Rate of recurrent isthmus conduction in the anterior, middle or posterior third of the isthmus.
Time frame: 3 months
Freedom from recurrence of Atrial flutter
Time frame: 3 and 12 months
Occurrence of bidirectional isthmus block with the first ablation line.
Time frame: 1 hour
Rate of permanent reconduction on the table
Time frame: 10 minutes
Rate of transient reconduction on the table with adenosine
Time frame: 10 minutes
Ablation time needed to achieve bidirectional isthmus block
Time frame: 1 hour
Total ablation time
Time frame: 1 hour
Total procedure time
Time frame: 1 hour
Quality of Life assesing patients symptoms
Time frame: 12 months
Contact Force (CF)
Time frame: 1 hour
Force-time-integral (FTI)
Time frame: 1 hour
Lesion-size-index (LSI)
Time frame: 1 hour
Reasons for reconduction
Time frame: 3 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Oct 2020.
- Individual participant dataSharing planned: No. We are not authorized to share individual participant data
Related trials for Atrial Flutter
Recruiting
Anatomical Navigation for Guided Electrophysiology in AFL and AFib
Atrial Fibrillation, Atrial Flutter
Recruiting
Feasibility Study on the VERAFEYE Imaging and Navigation System for Guided Catheter Ablation Procedures
Atrial Fibrillation, Atrial Flutter
RecruitingObservational study
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
Chronic Lymphocytic Leukemia (CLL), Waldenstr(SqrRoot)(Delta)m s Macroglobulinemia
Active, not recruiting
Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System
Persistent Atrial Fibrillation
Recruiting
Pericardiotomy in Cardiac Surgery
Atrial Fibrillation, Atrial Flutter
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jens Cosedis Nielsen, MD, DMsci study chair
Aarhus University Hospital Skejby
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing RFA in people with Atrial Flutter, run by Aarhus University Hospital Skejby at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Oct 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of recurrent isthmus conduction (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Oct 2020.